SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 21st, 2022 • General Atlantic, L.P. • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of July 15, 2022 (the “Execution Date”) by and among Immunocore Holdings plc (registered number 13119746), a public limited company incorporated in England and Wales whose registered office is at 92 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY United Kingdom (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
DATED JANUARY 22, 2021 THE SERIES C INVESTORS and THE SERIES B INVESTORS and THE SERIES A INVESTORS and THE QUALIFYING ORDINARY SHAREHOLDERS and IMMUNOCORE HOLDINGS LIMITED SHAREHOLDERS’ AGREEMENT relating to Immunocore Holdings Limited ContentsShareholder Agreement • July 21st, 2022 • General Atlantic, L.P. • Biological products, (no disgnostic substances) • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 21st, 2022 • General Atlantic, L.P. • Biological products, (no disgnostic substances) • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of July 15, 2022, by and among Immunocore Holdings plc, a public limited company incorporated in England and Wales with Company number 13119746 (the “Company”), and the investors listed on the attached Schedule A who are signatories to this Agreement (individually as an “Investor” and collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
